title: L-Canavanine potentiates the cytotoxicity of doxorubicin and cisplatin in arginine deprived human cancer cells.
abstract: The non-protein amino acid L-canavanine (L-CAV), an antimetabolite of L-arginine (L-ARG), can alter the 3D conformation of proteins when incorporated into a protein instead of L-ARG. L-CAV inhibits the proliferation of some tumour cells. The deprivation of L-ARG in the culture medium enhances the response of cells to L-CAV. This study aimed to investigate the interaction of L-CAV in combination with the chemotherapeutic drugs, doxorubicin (DOX) or cisplatin (CIS), in cancer cells, especially in the absence of L-ARG. A combination method based on the median-effect principle and mass-action law was used. The following cancer cells were employed: HeLa and Caco-2 cells, overexpressing argininosuccinate synthase (ASS), pancreatic cells (MIA PaCa-2 and BxPC-3) and hepatocellular carcinoma cells (Hep G2 and SK-HEP-1), with down-regulated ASS. When constant and non-constant ratios of L-CAV were combined with DOX and CIS, a synergistic potentiation of cytotoxicity was recorded. Cells expressing high levels of ASS were more sensitive to the treatment as compared to the cells with reduced ASS levels. Overall, this study may provide a new approach to targeting some cancer cells with L-CAV in combination with DNA-targeting drugs such as DOX and CIS, especially those cells which overexpress ASS, such as human cervical and colorectal carcinoma cells.
authors.affiliation: Institute of Pharmacy and Molecular Biotechnology, Heidelberg University , Heidelberg , Germany.
authors.forename: Agustina Dr
authors.initials: AD
authors.lastname: Nurcahyanti
authors.affiliation: Institute of Pharmacy and Molecular Biotechnology, Heidelberg University , Heidelberg , Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Wink
keywords: Argininosuccinate synthase (ASS); Cisplatin; Doxorubicin; L-arginine; L-canavanine; Synergy
references.citation: Toxicol Appl Pharmacol. 1987 Dec;91(3):395-405
references.pmid: 2447682
references.citation: Anticancer Drugs. 1995 Aug;6(4):586-93
references.pmid: 7579563
references.citation: Life Sci. 1997;60(19):1635-41
references.pmid: 9129118
references.citation: Nat Rev Cancer. 2011 Sep 23;11(10):708-18
references.pmid: 21941282
references.citation: Br J Cancer. 2000 Sep;83(6):800-10
references.pmid: 10952786
references.citation: Curr Protoc Immunol. 2001 May;Appendix 3:Appendix 3B
references.pmid: 18432654
references.citation: Phytomedicine. 2012 Nov 15;19(14):1288-97
references.pmid: 23146422
references.citation: Nat Rev Drug Discov. 2005 Apr;4(4):307-20
references.pmid: 15789122
references.citation: Anticancer Drugs. 2002 Mar;13(3):313-20
references.pmid: 11984075
references.citation: J Cell Physiol. 1993 Feb;154(2):419-32
references.pmid: 8425921
references.citation: Melanoma Res. 1992 Sep;2(3):191-6
references.pmid: 1450673
references.citation: Pharmacol Rev. 2006 Sep;58(3):621-81
references.pmid: 16968952
references.citation: Cancer Res. 1959 Jan;19(1):122-5
references.pmid: 13618897
references.citation: Mol Cell Biochem. 2003 Feb;244(1-2):37-43
references.pmid: 12701807
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7660-8
references.pmid: 16234528
references.citation: Am J Physiol Cell Physiol. 2012 Feb 15;302(4):C676-85
references.pmid: 22116304
references.citation: Curr Pharm Des. 2008;14(11):1049-57
references.pmid: 18473854
references.citation: Cancer Res. 1986 Jun;46(6):2898-903
references.pmid: 3698016
references.citation: BMC Cancer. 2014 Sep 20;14:686
references.pmid: 25240403
references.citation: J Agric Food Chem. 2003 May 7;51(10):2854-65
references.pmid: 12720365
references.citation: Drug Target Insights. 2007;2:119-28
references.pmid: 21901069
references.citation: Cancer. 2004 Feb 15;100(4):826-33
references.pmid: 14770441
references.citation: Pharmacogenet Genomics. 2011 Jul;21(7):440-6
references.pmid: 21048526
references.citation: Cancer Res. 1994 Dec 1;54(23):6045-8
references.pmid: 7954443
references.citation: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references.pmid: 6606682
references.citation: Cancer Lett. 1998 Oct 23;132(1-2):229-39
references.pmid: 10397478
references.citation: Z Naturforsch C. 2007 May-Jun;62(5-6):458-66
references.pmid: 17708454
references.citation: Biochem Biophys Res Commun. 2002 Jul 12;295(2):283-8
references.pmid: 12150944
references.citation: J Biol Chem. 1990 Jul 5;265(19):11377-81
references.pmid: 2358467
references.citation: J Biol Chem. 1989 Aug 15;264(23):13693-6
references.pmid: 2760038
references.citation: J Nutr. 2004 Oct;134(10 Suppl):2837S-2841S; discussion 2853S
references.pmid: 15465796
references.citation: Cancer Res. 1980 Mar;40(3):535-7
references.pmid: 7471074
references.citation: PLoS One. 2009;4(5):e5620
references.pmid: 19440335
references.citation: J Clin Oncol. 2004 May 15;22(10 ):1815-22
references.pmid: 15143074
references.citation: Cancers (Basel). 2011 Mar 15;3(1):1351-71
references.pmid: 24212665
references.citation: Int J Cancer. 2010 Jun 15;126(12):2762-72
references.pmid: 20104527
references.citation: Cytobios. 1981;30(118):101-26
references.pmid: 7196826
references.citation: J Biol Chem. 1983 Mar 25;258(6):3446-52
references.pmid: 6300044
references.citation: J Virol. 1980 Mar;33(3):954-61
references.pmid: 7365878
references.citation: Eur J Biochem. 2003 May;270(9):1887-99
references.pmid: 12709047
references.citation: Int J Cancer. 2008 Oct 15;123(8):1950-5
references.pmid: 18661517